Genomes and Genes
Summary: Activated form of factor VII. Factor VIIa activates factor X in the extrinsic pathway of blood coagulation.
Publications279 found, 100 shown here
- Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cellsXiaofeng Jiang
Sol Sherry Thrombosis Research Center, Temple University School of Medicine, 3400 North Broad Street Room 300 OMS, Philadelphia, PA 19140, USA
Thromb Haemost 100:127-33. 2008..Targeting the TF-mediated cell signaling pathway might represent a novel strategy for the treatment of breast cancer...
- Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endotheliumSamit Ghosh
Biomedical Research Division, The University of Texas Health Center at Tyler, Tyler, Texas 75708, USA
J Biol Chem 282:11849-57. 2007Although factor VII/factor VIIa (FVII/FVIIa) is known to interact with many non-vascular cells, activated monocytes, and endothelial cells via its binding to tissue factor (TF), the interaction of FVII/FVIIa with unperturbed endothelium ..
- Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protectionProsenjit Sen
Center for Biomedical Research, The University of Texas Health Science Center at Tyler, Tyler, TX, USA
Blood 117:3199-208. 2011Recent studies have shown that factor VIIa (FVIIa) binds to the endothelial cell protein C receptor (EPCR), a cellular receptor for protein C and activated protein C, but the physiologic significance of this interaction is unclear...
- Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhageCarl J Hauser
Department of Surgery, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts 02216, USA
J Trauma 69:489-500. 2010Traumatic coagulopathy contributes to early death by exsanguination and late death in multiple organ failure. Recombinant Factor VIIa (rFVIIa, NovoSeven) is a procoagulant that might limit bleeding and improve trauma outcomes.
- Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhageStephan A Mayer
Department of Neurology, Columbia University College of Physicians and Surgeons, New York, USA
N Engl J Med 358:2127-37. 2008..We performed this phase 3 trial to confirm a previous study in which recombinant activated factor VII (rFVIIa) reduced growth of the hematoma and improved survival and functional outcomes...
- Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surfaceS Ghosh
Biomedical Research Division, The University of Texas Health Center at Tyler, Tyler, TX 75708, USA
J Thromb Haemost 5:336-46. 2007Variants of recombinant factor VIIa (rFVIIa) with increased intrinsic activity have been developed to improve efficacy in the treatment of bleeding disorders in the future...
- Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombastheniaM C Poon
Departments of Medicine, Pediatrics, and Oncology, University of Calgary and Foothills Hospital, Calgary, Alberta, Canada
Blood 94:3951-3. 1999..No adverse effects of rFVIIa were observed. Although the number of patients is small, our study suggests that rFVIIa may be an alternative to platelet transfusions in patients with a severe congenital thrombocytopathy...
- Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trialJaime Bosch
Hepatic Hemodynamic Laboratory, Hospital Clinic and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, University of Barcelona, Spain
Hepatology 47:1604-14. 2008..A marked heterogeneity in the failure rate in all treatment groups was observed across participating centers. Adverse events, including overall thromboembolic events, were comparable between groups...
- Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indicationsVeronica Yank
Stanford University, Stanford, CA, USA
Ann Intern Med 154:529-40. 2011Recombinant factor VIIa (rFVIIa), a hemostatic agent approved for hemophilia, is increasingly used for off-label indications.
- Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital recordsAaron C Logan
Stanford University School of Medicine, Stanford, CA, USA
Ann Intern Med 154:516-22. 2011Recombinant factor VIIa (rFVIIa) is approved for treatment of bleeding in patients who have hemophilia with inhibitors but has been applied to a wide range of off-label indications.
- Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligandVijender R Vaidyula
Temple University Hospital, 3401 North Broad Street, Philadelphia, PA 19140, USA
Diabetes 55:202-8. 2006..2, factor VIII coagulant activity, and platelet CD40 ligand as well as decreases in factor VIIa, factor VII coagulant activities, and factor VII antigen...
- Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeysThomas W Geisbert
Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA
Lancet 362:1953-8. 2003..Here, we tested the notion that blockade of fVIIa/tissue factor is beneficial after infection with Ebola virus...
- Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanismTodd A Hembrough
EntreMed, Inc, Laboratory of Discovery Research, Rockville, Maryland 20850, USA
Cancer Res 63:2997-3000. 2003..coagulation on tumor growth, in vivo, we tested coagulation inhibitors specific for either tissue factor (TF)/factor VIIa (fVIIa) complexes or factor Xa (fXa) for antitumor activity...
- Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophiliaJ N Mahlangu
Hemophilia Comprehensive Care Center, Charlotte Maxeke Johannesburg Academic Hospital and University of Witwatersrand, Johannesburg, South Africa
J Thromb Haemost 10:773-80. 2012BAY 86-6150 is a new human recombinant factor VIIa variant developed for high procoagulant activity and longer action in people with hemophilia with inhibitors.
- Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)R Gopalakrishnan
Center for Biomedical Research, The University of Texas Health Science Center, Tyler, TX 75703, USA
J Thromb Haemost 8:301-10. 2010Recent clinical studies suggest that the prophylactic use of recombinant factor VIIa (rFVIIa) markedly reduces the number of bleeding episodes in hemophilic patients with inhibitors...
- Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasisB M Mueller
Department of Immunology, Scripps Research Institute, La Jolla, California 92037, USA
J Clin Invest 101:1372-8. 1998..Thus, extracellular functions of the catalytically active TF-VIIa complex cooperate with specific functions of the TF cytoplasmic domain to support the complex process of hematogenous tumor cell dissemination...
- Plasma elimination kinetics for factor VII are independent of its activation to factor VIIa and complex formation with plasma inhibitorsLars C Petersen
Haemostasis Biology, Health Care Discovery, Novo Nordisk, Maalov, Denmark
Thromb Haemost 101:818-26. 2009..All FVII derivatives studied including FVII, FVIIa and FVIIa-AT were cleared with similar rates suggesting an elimination kinetics which is unaffected by FVII activation and subsequent inactivation by plasma inhibitors...
- Raising the active site of factor VIIa above the membrane surface reduces its procoagulant activity but not factor VII autoactivationEmily K Waters
Department of Biochemistry, College of Medicine, University of Illinois at Urbana Champaign, Urbana, Illinois 61801, USA
J Biol Chem 281:26062-8. 2006..trigger of blood clotting, is the membrane-anchored protein cofactor for the plasma serine protease, factor VIIa. Tissue factor is hypothesized to position and align the active site of factor VIIa relative to the membrane ..
- Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia ADonald F Brophy
School of Pharmacy, Coagulation Advancement Laboratory, Virginia Commonwealth University, Richmond, VA, USA
Blood Coagul Fibrinolysis 21:539-46. 2010..HAS and TEG assays provided similar estimates of FOT and R, however CEM appeared to be more sensitive than MA to changes in clot firmness...
- Endothelial cell protein C receptor cellular localization and trafficking: potential functional implicationsRamesh C Nayak
Center for Biomedical Research, University of Texas Health Science Center at Tyler, Tyler, TX 75708, USA
Blood 114:1974-86. 2009..A small fraction of EPCR is also localized intracellularly in the recycling compartment. Factor VIIa (FVIIa) or activated protein C binding to EPCR promoted the internalization of EPCR...
- Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trialErich V de Paula
Hematology and Hemotherapy Center, University of Campinas, Sao Paulo, Brazil
J Thromb Haemost 10:81-9. 2012A recombinant factor VIIa analog (NN1731; vatreptacog alfa [activated]) was developed to provide safe, rapid and sustained resolution of bleeds in patients with hemophilia and inhibitors.
- Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit modelAnne Godier
Department of Anaesthesia and Critical Care, Paris Descartes University, Hotel Dieu University Hospital, Paris, France
Anesthesiology 116:94-102. 2012....
- Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cellsXiaofeng Jiang
Temple University School of Medicine, Sol Sherry Thrombosis Research Center, Philadelphia, PA 19140, USA
Thromb Haemost 96:196-201. 2006Tissue factor (TF) is a transmembrane glycoprotein that initiates blood coagulation when complexed with factor VIIa (FVIIa)...
- The use of recombinant activated factor VII in trauma patients: Experience from the Australian and New Zealand haemostasis registryPeter Cameron
Department of Epidemiology and Preventive Medicine, Monash University and Alfred Hospital Emergency and Trauma Centre, Melbourne, Australia
Injury 38:1030-8. 2007..The role of rFVIIa is not defined in this group of patients. Registries provide an opportunity to review the patients, reported response and adverse events for rFVIIa...
- Binding of factor VIIa to the endothelial cell protein C receptor reduces its coagulant activityJ López-Sagaseta
Haematology Department and the Division of Cardiovascular Sciences, Laboratory of Thrombosis and Haemostasis, Clinica Universitaria School of Medicine, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain
J Thromb Haemost 5:1817-24. 2007..Factor VII (FVII), the coagulation trigger upon tissue factor (TF) interaction, is a serine protease whose Gla domain is highly homologous to the Gla domain of protein C...
- Tissue factor-factor VIIa complex induces epithelial ovarian cancer cell invasion and metastasis through a monocytes-dependent mechanismZhengwen Ma
Department of Neurobiology, Shanghai Jiaotong University School of Medicine, Shanghai, China
Int J Gynecol Cancer 21:616-24. 2011..However, it is not clear how tumor-associated macrophage and TF-FVIIa complex promotes EOC invasion. In the present study, we aimed to determine the mechanism by which interaction of TF-FVIIa and monocytes (MOs) promotes EOC metastasis...
- Safety profile of recombinant factor VIIaHarold R Roberts
Division of Hematology, Center for Thrombosis and Hemostasis, University of North Carolina at Chapel Hill, USA
Semin Hematol 41:101-8. 2004Recombinant factor VIIa (rFVIIa; NovoSeven(R), Novo Nordisk, Bagsvaerd, Denmark) has been used for many years in the successful management of bleeding episodes in patients with hemophilia and inhibitors...
- The role of tissue factor and factor VIIa in hemostasisNigel Mackman
Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, NC 27599 7035, USA
Anesth Analg 108:1447-52. 2009..However, the mechanism by which recombinant FVIIa restores hemostasis has not been clearly defined. In conclusion, the TF:FVIIa complex is essential for hemostasis and recombinant FVIIa is an effective hemostatic drug...
- Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsyLennox Jeffers
Center for Liver Disease, University of Miami School of Medicine, Miami, Florida 33125, USA
Gastroenterology 123:118-26. 2002....
- Kinetic modeling sheds light on the mode of action of recombinant factor VIIa on thrombin generationAlexander Y Mitrophanov
DoD Biotechnology High Performance Computing Software Applications Institute, Telemedicine and Advanced Technology Research Center, US Army Medical Research and Materiel Command, ATTN MCMR TT, 504 Scott Street, Ft Detrick, MD 21702, USA
Thromb Res 128:381-90. 2011..To elucidate the inherent ability of rFVIIa to modulate thrombin production, it is necessary to identify rFVIIa-induced effects that are compatible with the available biochemical knowledge about thrombin generation mechanisms...
- Structure of human factor VIIa and its implications for the triggering of blood coagulationA C Pike
Structural Biology Laboratory, Chemistry Department, University of York, York YO10 5DD, United Kingdom
Proc Natl Acad Sci U S A 96:8925-30. 1999b>Factor VIIa (EC 188.8.131.52) is a trypsin-like serine protease that plays a key role in the blood coagulation cascade. On injury, factor VIIa forms a complex with its allosteric regulator, tissue factor, and initiates blood clotting...
- Recombinant factor VIIa: its background, development and clinical useUlla Hedner
University of Lund, Sweden
Curr Opin Hematol 14:225-9. 2007..For the first time it was shown that pharmacological doses of FVIIa induced hemostasis...
- First 20 years with recombinant FVIIa (NovoSeven)U Hedner
Department of Medicine, University of Lund, Lund, Sweden
Haemophilia 17:e172-82. 2011..By exploiting this mechanism of action, rFVIIa may also be effective in situations other than haemophilia, characterized by an impaired thrombin generation...
- Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trialBarton Sachs
Texas Back Institute Clinical Research Organization, Plano, TX, USA
Spine (Phila Pa 1976) 32:2285-93. 2007..Randomized, placebo-controlled, double-blind, multicenter, Phase IIa study...
- Back to the future: a recent history of haemophilia treatmentP M Mannucci
Department of Medicine and Medical Specialties, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, University of Milan and IRCCS Maggiore Hospital, Milan, Italy
Haemophilia 14:10-8. 2008....
- Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activationB Sørensen
Center for Haemophilia and Thrombosis, Department of Clinical Immunology, Aarhus University Hospital, Skejby, Denmark
J Thromb Haemost 1:551-8. 2003..Preliminary studies in patients substituted with recombinant factor VIIa demonstrated a marked change in the coagulation profile, in which the MaxVel and t,MaxVel shifted towards ..
- Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell diseaseN S Key
Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA
Blood 91:4216-23. 1998..Because TF is the principal cellular ligand for FVIIa, it is possible that increased binding to TF accounts for the diminished plasma FVIIa levels...
- Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjectsEvert de Jonge
Department of Intensive Care, Academic Medical Center, University of Amsterdam, The Netherlands
Clin Diagn Lab Immunol 10:495-7. 2003..we report that the activation of coagulation in healthy human subjects by the administration of recombinant factor VIIa also elicits a small but significant increase in the concentrations of interleukin 6 (IL-6) and IL-8 in plasma...
- Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive traumaUri Martinowitz
National Hemophilia Center, Tel Hashomer, Israel
Can J Anaesth 49:S15-20. 2002..It is approved for use in hemophilia patients, however, its use in trauma is still controversial due to the theoretical risk of thromboembolic complications...
- Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trialsSandro B Rizoli
Department of Surgery and Critical Care Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, M4N 3M5 Canada
Crit Care 10:R178. 2006We conducted a post-hoc analysis on the effect of recombinant factor VIIa (rFVIIa) on coagulopathic patients from two randomized, placebo-controlled, double-blind trials of rFVIIa as an adjunctive therapy for bleeding in patients with ..
- Herpes simplex virus type 1-encoded glycoprotein C enhances coagulation factor VIIa activity on the virusMichael R Sutherland
Canadian Blood Services, Research and Development Department, Canada
Thromb Haemost 92:947-55. 2004Tissue factor (TF) is the blood coagulation initiator, whose cofactor function is required for physiological factor VIIa (FVIIa)-mediated activation of factor X (FX) to FXa...
- Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitorsAshish V Joshi
Novo Nordisk Inc, Princeton, NJ, USA
Curr Med Res Opin 22:23-31. 2006....
- Factor viia for alveolar hemorrhage in microscopic polyangiitisAlan D Betensley
Am J Respir Crit Care Med 166:1291-2. 2002
- Probing the interface between factor Xa and tissue factor in the quaternary complex tissue factor-factor VIIa-factor Xa-tissue factor pathway inhibitorKarin Carlsson
IFM Department of Chemistry, Linkoping University, Linkoping, Sweden
Eur J Biochem 270:2576-82. 2003Blood coagulation is triggered by the formation of a complex between factor VIIa (FVIIa) and its cofactor, tissue factor (TF)...
- Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulantsKellie A Vavra
Pharmacy Department, Kaiser Permanente Colorado, Aurora, USA
Ann Pharmacother 44:718-26. 2010To evaluate the use of recombinant factor VIIa (rFVIIa) to reverse major bleeding from newer parenteral anticoagulant therapy.
- The use of recombinant factor VIIa in the treatment of bleeding disordersHarold R Roberts
Division of Hematology Oncology, Department of Medicine and The Carolina Cardiovascular Biology Center, 932 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 7035, USA
Blood 104:3858-64. 2004Recombinant factor VIIa was initially developed for the treatment of hemorrhagic episodes in hemophilic patients with inhibitors to factors VIII and IX...
- Treatment with anti-factor VIIa in acute pancreatitis in rats: blocking both coagulation and inflammation?Ellen Andersson
Department of Surgery, Lund University Hospital, Lund, Sweden
Scand J Gastroenterol 42:765-70. 2007..Several inhibitors of the coagulation cascade, including active-site-inactivated factor VIIa, have shown anti-inflammatory properties in other inflammatory models than acute pancreatitis...
- Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registryH Chambost
Paediatric Haematology Department, APHM, Children s Hospital La Timone, Marseille, France INSERM, UMR 1062, Aix Marseille University, Marseille, France
Haemophilia 19:571-7. 2013The ONE Registry (OR) was an international prospective observational study of on-demand recombinant factor VIIa (rFVIIa) treatment for mild to moderate bleeds in haemophilia A/B patients with inhibitors...
- Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in ratsB Lauritzen
Research and Development, Novo Nordisk A S, Måløv, Denmark
J Thromb Haemost 6:804-11. 2008..Heparin can readily be antagonized with protamine, but this is less effective against LMWH...
- Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disordersAna Maria Galán
Hematherapy and Hemostasis Service, Hospital Clinic, Faculty of Medicine, IDIBAPS, Barcelona, Spain
Transfusion 43:885-92. 2003....
- Use of recombinant factor VIIa in inherited and acquired von Willebrand diseaseChristoph Sucker
Department of Hemostasis and Transfusion Medicine, Heinrich Heine University Medical Center, Dusseldorf, Germany
Clin Appl Thromb Hemost 15:27-31. 2009Recombinant factor VIIa (rFVIIa) is increasingly used outside the labeled indications for the treatment of life-threatening bleeding episodes after failure of respective standard therapy...
- Current insights on the risk of thrombogenicity with off-label use of rFVllaNigel Key
Division of Hematology, University of North Carolina, Chapel Hill, NC, USA
Clin Adv Hematol Oncol 4:34-5. 2006
- The tissue factor/factor VIIa/factor Xa complex: a model built by docking and site-directed mutagenesisBrian V Norledge
The Scripps Research Institute, La Jolla, California 92037, USA
Proteins 53:640-8. 2003Factor X is activated to factor Xa (fXa) in the extrinsic coagulation pathway by the tissue factor (TF)/factor VIIa (fVIIa) complex...
- Factor VII mutant V154G models a zymogen-like form of factor VIIaRaffaella Toso
Department of Biochemistry and Molecular Biology, University of Ferrara, Via Luigi Borsari, 46 Ferrara 44100, Italy
Biochem J 369:563-71. 2003....
- Seminal factor VII and factor VIIa: supporting evidence for the presence of an active tissue factor-dependent coagulation pathway in human semenBashir A Lwaleed
Department of Urology, Southampton University Hospitals NHS Trust, Southampton, UK
Int J Androl 30:543-9. 2007..This finding reinforces the concept of an active clotting system in human semen, by establishing the missing link in the activation of a TF-dependent pathway...
- Changing from aprotinin to tranexamic acid results in increased use of blood products and recombinant factor VIIa for aortic surgery requiring hypothermic arrestRoman M Sniecinski
Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA 30322, USA
J Cardiothorac Vasc Anesth 24:959-63. 2010..This study was undertaken to determine what, if any, the impact of changing antifibrinolytic agents (from aprotinin to tranexamic acid) for deep hypothermic circulatory arrest cases would have on blood bank resource utilization...
- The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0E Erhardtsen
Novo Nordisk A S, Copenhagen, Denmark
Blood Coagul Fibrinolysis 9:741-8. 1998..coagulation factors, decreases during oral anticoagulant therapy and the administration of recombinant factor VIIa normalizes the prolonged prothrombin time in warfarin-treated rats...
- Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patientsH Agersø
Pharmacology, Biopharmaceuticals Research Unit, Novo Nordisk A S, Maaloev, Denmark
J Thromb Haemost 9:333-8. 2011..The objective of the present study was to evaluate the pharmacokinetics and the clearance pathways of rFVIIa after intravenous administration to hemophilia patients...
- Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IXH Ekert
Haemophilia Treatment Centre, Royal Children s Hospital, Flemington Road, Parkville, Victoria, Australia
Haemophilia 7:279-85. 2001..Quality-of-life improvements were observed in several important areas as perceived by both patients and their families, at an incremental cost per QALY of A$51 533...
- Tissue factor positions and maintains the factor VIIa active site far above the membrane surface even in the absence of the factor VIIa Gla domain. A fluorescence resonance energy transfer studyC D McCallum
Department of Medical Biochemistry and Genetics, Texas A and M University, College Station, Texas 77843, USA
J Biol Chem 272:30160-6. 1997Coagulation factor VIIa (fVIIa), a soluble serine protease, exhibits full proteolytic activity only when bound to its cofactor, tissue factor (TF)...
- Factor VIIa-tissue factor: functional importance of protein-membrane interactionsJ H Morrissey
Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City 73104, USA
Thromb Haemost 78:112-6. 1997The first enzyme in the blood clotting cascade consists of two distinct protein subunits: a catalytic subunit (factor VIIa; FVIIa) and an essential regulatory subunit (tissue factor; TF)...
- Rational design of coagulation factor VIIa variants with substantially increased intrinsic activityE Persson
Vascular Biochemistry, Novo Nordisk A S, Novo Nordisk Park, DK 2760 Måløv, Denmark
Proc Natl Acad Sci U S A 98:13583-8. 2001..The FVIIa analogues promise to offer a more efficacious treatment of bleeding episodes especially in hemophiliacs with inhibitory antibodies precluding conventional replacement therapy...
- Relationships of plasma factor VIIa-antithrombin complexes to manifest and future cardiovascular diseaseAngela Silveira
Cardiovascular Genetics Group, Atherosclerosis Research Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Thromb Res 130:221-5. 2012..VIIa also circulates in inactive form, in complex with antithrombin (VIIaAT) formed when VIIa is bound to tissue factor (TF). This study evaluated VIIaAT in relation to cardiovascular disease (CVD)...
- An Arg/Ser substitution in the second epidermal growth factor-like module of factor IX introduces an O-linked carbohydrate and markedly impairs activation by factor XIa and factor VIIa/Tissue factor and catalytic efficiency of factor IXaM S Hertzberg
Department of Haematology, Westmead Hospital and University of Sydney, Sydney, New South Wales, Australia
Blood 94:156-63. 1999..Recombinant factor IXR94S was activated by factor XIa/calcium with an approximately 50-fold reduced rate and by factor VIIa/tissue factor/phospholipid/calcium with an approximately 20-fold reduced rate compared with wild-type factor IX...
- Active site-inactivated factor VIIa inhibits nuclear factor kappa B activation in intestinal ischemia and reperfusionMaria M Stollenwerk
Faculty of Health and Society, Malmo University, Malmo, Sweden
J Surg Res 178:692-9. 2012..Intestinal I/R injury initiates the extrinsic tissue factor or factor VIIa-dependent pathway of coagulation, also of importance in multiple organ dysfunction syndrome...
- New direct oral anticoagulants--current therapeutic options and treatment recommendations for bleeding complicationsWolfgang Miesbach
Medical Clinic III, Institute of Transfusion Medicine, University Hospital, Frankfurt Main, Germany
Thromb Haemost 108:625-32. 2012..This review summarises potential bleeding management options and available data on the new DOAs...
- Factor VIIa binding to endothelial cell protein C receptor: differences between mouse and human systemsProsenjit Sen
Center for Biomedical Research, The University of Texas Health Science Center at Tyler, Tyler, Texas 75708, USA
Thromb Haemost 107:951-61. 2012..Our data suggest that one should consider the use of human FVIIa in mouse models to investigate the significance of FVIIa and EPCR interaction...
- Analysis of the site-specific asparagine-linked glycosylation of recombinant human coagulation factor VIIa by glycosidase digestions, liquid chromatography, and mass spectrometryN K Klausen
Department of Protein Chemistry Ge, Novo Nordisk A S, Gentofte, Denmark
Mol Biotechnol 9:195-204. 1998The two asparagine-linked glycosylation sites of recombinant coagulation factor VIIa have been characterized by glycosidase digestions, size-exclusion chromatography (SEC), and mass spectrometry (MS)...
- Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole bloodDaniel Dirkmann
Klinik für Anästhesiologie und Intensivmedizin, Universität Duisburg Essen and Universitätsklinikum Essen, Essen, Germany
Anesth Analg 114:1182-8. 2012..We tested the hypotheses that FXIII concentrate, prothrombin complex concentrate (PCC), recombinant factor VIIa (rFVIIa), and tranexamic acid (TA) inhibit fibrinolysis to different degrees, and that platelets contribute to ..
- Augmented intrinsic activity of Factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancementEgon Persson
Haemostasis Biochemistry, Novo Nordisk A S, Novo Nordisk Park, DK 2760 Måløv, Denmark
Biochem J 379:497-503. 2004Coagulation Factor VIIa (FVIIa) lacks the ability to spontaneously complete the conversion to a fully active enzyme after specific cleavage of an internal peptide bond (Arg152-Ile153) in the zymogen...
- The location of the active site of blood coagulation factor VIIa above the membrane surface and its reorientation upon association with tissue factor. A fluorescence energy transfer studyC D McCallum
Department of Medical Biochemistry and Genetics, Texas A and M University Health Science Center, College Station, Texas 77843 1114, USA
J Biol Chem 271:28168-75. 1996The topography of membrane-bound blood coagulation factor VIIa (fVIIa) was examined by positioning a fluorescein dye in the active site of fVIIa via a tripeptide tether to yield fluorescein-D-phenylalanyl-L-prolyl-L-arginyl-fVIIa (Fl-FPR-..
- Redistribution and hemostatic action of recombinant activated factor VII associated with plateletsIrene Lopez-Vilchez
Hemotherapy and Hemostasis Service, Hospital Clinic, Biomedical Diagnostics Center CDB, Institute of Biomedical Research August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
Am J Pathol 178:2938-48. 2011..Redistribution of rFVIIa into platelets may explain the prolonged prophylactic effectiveness of rFVIIa in hemophilia...
- Dysinosins B-D, inhibitors of factor VIIa and thrombin from the Australian sponge Lamellodysidea chloreaAnthony R Carroll
Natural Product Discovery, Eskitis Institute, Griffith University, Brisbane, Queensland, Australia 4111
J Nat Prod 67:1291-4. 2004..These compounds are inhibitors of the blood coagulation cascade serine proteases factor VIIa and thrombin...
- Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarolP Girard
Clinical Pharmacology Unit, EA 643 University Claude Bernard, Hopital Cardiologique, Lyon, France
Thromb Haemost 80:109-13. 1998..The dose producing 50% of the maximum drop of INR was estimated to be 2.2 microg/kg. The model will be used to better define the dosage regimen for future clinical developments...
- Recombinant factor VIIa: a useful tool for life-threatening colonic bleeding. Report of a caseJ G Mitchell
Department of Colorectal Surgery, Queens Medical Centre, Nottingham, United Kingdom
Dis Colon Rectum 50:2238-40. 2007
- A clinical review of bleeding dilemmas in traumaDavid B Hoyt
Department of Surgery, University of California, San Diego, USA
Semin Hematol 41:40-3. 2004..This paper reviews recent developments and controversies in trauma care, and, in particular, the potential role of procoagulant therapy using recombinant factor VIIa in the prevention of mortality due to bleeding.
- Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disordersKatherine F Croom
Wolters Kluwer Health Adis, Auckland, New Zealand
BioDrugs 22:121-36. 2008Recombinant factor VIIa (NovoSeven; also known as recombinant activated factor VII or eptacog alfa) is structurally similar to human plasma-derived coagulation factor VIIa, but is manufactured using DNA biotechnology...
- Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet countT Lisman
Thrombosis and Hemostasis Laboratory, Department of Hematology, University Medical Center, Utrecht, The Netherlands
J Thromb Haemost 3:742-51. 2005Recombinant factor VIIa (rFVIIa), which was developed for treatment of inhibitor-complicated hemophilia, appears suitable as prohemostatic agent in other clinical disorders including patients with thrombocytopenia...
- Successful treatment of severe gastrointestinal bleeding secondary to Crohn disease with recombinant factor VIIaEva Girona
Gastroenterology Section, Critical Care Unit, Hospital General Universitario de Elche, Spain
South Med J 100:601-4. 2007..In this case, the use of recombinant activated factor VIIa controlled the massive gastrointestinal bleeding secondary to Crohn disease and without clinically significant ..
- The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasisMaureane Hoffman
Dis Mon 49:14-21. 2003..We have previously proposed a platelet-dependent mechanism of action for high-dose factor VIIa (FVIIa; Novoseven, Novo Nordisk, Copenhagen, Denmark)...
- Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIaK Hicks
Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Bone Marrow Transplant 30:975-8. 2002..The syndrome is associated with a high mortality rate; and current treatment options are limited. Recombinant factor VIIa (rFVIIa, Novoseven) has recently been approved for the treatment of bleeding in patients with hemophilia A/B ..
- The use of recombinant factor VIIa in severe postpartum hemorrhageShmuel Segal
Barzilai Medical Center, Ashkelon, Israel
Acta Obstet Gynecol Scand 83:771-2. 2004
- Acquired hemophilia A: clinical features, surgery and treatment of 34 cases, and experience of using recombinant factor VIIaManijeh Lak
Hematology Department, Hemophilia Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
Clin Appl Thromb Hemost 16:294-300. 2010..4%), 5 partial efficient treatment (14.7%) and two treatments inefficient (5.9%). Elimination therapy using steroid alone or with combination can terminate complete remission in most cases...
- Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VIIStephan Malherbe
Department of Anesthesiology and Pain Medicine, University of Alberta, Edmonton, Canada
Anesthesiology 100:443-5. 2004
- Use of recombinant factor VIIa in inherited platelet disordersMohamed Kaleelrahman
Br J Haematol 125:95-6. 2004
- Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trialRaj K Narayan
Department of Neurosurgery, University of Cincinnati, Cincinnati, Ohio, USA
Neurosurgery 62:776-86; discussion 786-8. 2008..Recombinant factor VIIa (rFVIIa) is a hemostatic agent that has been shown to limit hemorrhage expansion and which, therefore, could ..
- Caesarean section for placenta praevia complicated by postpartum haemorrhage managed successfully with recombinant activated human coagulation Factor VIIaM Gidiri
Department of Obstetrics and Gynaecology, Hull and East Yorkshire Women and Children s Hospital, Hull, UK
J Obstet Gynaecol 24:925-6. 2004
- Tissue Factor-Factor VIIa complex induces cytokine expression in coronary artery smooth muscle cellsG Demetz
Deutsches Herzzentrum und 1 Medizinische Klinik, Technische Universitat Munchen, Lazarettstr 36, 80636 Munich, Germany
Atherosclerosis 212:466-71. 2010Within atherosclerotic lesions Tissue Factor (TF)-Factor VIIa (FVIIa) not only contributes to thrombotic events but also alters vascular remodeling through enhancement of migration...
- Off-label reports of new biologics: exciting new therapy or dubious research? Examples from recombinant activated factor VIIWalter H Dzik
Blood Tranfusion Service, Massachusetts General Hospital, Boston, 02114, USA
J Intensive Care Med 21:54-9. 2006
- Factor VIIa regulates the expression of caspase-3, MMP-9, and CD44 in SW620 colon cancer cells involving PAR2/MAPKs/NF-κB signaling pathwaysYing Wu
Department of Internal Medicine, Affiliated Hospital of Jiangsu University, Jiangsu, PR China
Cancer Invest 31:7-16. 2013..The effects of FVIIa were TF-dependent and involving PAR2/MAPKs/NF-κB signal transduction pathways. Our study suggests that the links among PAR2/MAPKs/NF-κB may be blocked for effective treatments of colorectal cancers...
- Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safetyM Von Depka
Werlhof Institute for Haemostasis and Thrombosis, Karl Wiechert Allee, Hannover, Germany
Haemophilia 11:18-23. 2005..Recombinant FVIIa has demonstrated excellent efficacy and safety, even in patients refractory to other therapies...
- Cerebral sinus thrombosis in a trauma patient after recombinant activated factor VII infusionLeonie J Siegel
Department of Anesthesiology, Mannheim University Clinic, Germany
Anesthesiology 100:441-3. 2004
- Recombinant factor VIIa is associated with an improved 24-hour survival without an improvement in inpatient survival in massively transfused civilian trauma patientsBartolomeu Nascimento
Tory Regional Trauma Centre, Sunnybrook Health Sciences Centre, University of Toronto, Canada
Clinics (Sao Paulo) 66:101-6. 2011To determine whether recombinant factor VIIa (rFVIIa) is associated with increased survival and/or thromboembolic complications.
- Tissue factor enhances protease-activated receptor-2-mediated factor VIIa cell proliferative propertiesL Fan
Center de Recherche, Hopital Sainte Justine, Université de Montréal Montréal, Quebec, Canada
J Thromb Haemost 3:1056-63. 2005..We speculate that FVIIa-TF-PAR-2 inhibitors may be effective in suppressing cell proliferation...
- Successful treatment of severe retro-peritoneal bleeding with recombinant factor VIIa in women with placenta percreta invading into the left broad ligament: unusual repeated ante-partum intra-abdominal bleedingMuhieddine Seoud
Department of Obstetrics and Gynecology, American University of Beirut Medical Center, Beirut, Lebanon
J Obstet Gynaecol Res 36:183-6. 2010..bleedings in a woman with placenta percreta invading into the left broad ligament, in whom recombinant factor VIIa was effective for controlling severe retro-peritoneal bleeding...
- Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trialStephan A Mayer
Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY, USA
Neurocrit Care 4:206-14. 2006..We conducted this trial to evaluate the safety of activated recombinant factor VII (rFVIIa; NovoSeven) for preventing early hematoma growth in acute ICH...
- A novel use of recombinant factor VIIa in HELLP syndrome associated with spontaneous hepatic rupture and abdominal compartment syndromeBenjamin W Dart
Department of Surgery, Division of Surgical Critical Care, University of Tennessee College of Medicine, Chattanooga Unit, Chattanooga, Tennessee 37403, USA
J Trauma 57:171-4. 2004
- Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II studyJ Spira
Omri Laboratories Ltd, Nes Ziona, Israel
Haemophilia 16:910-8. 2010Recombinant activated factor VIIa (FVIIa) is a bypassing agent used to treat bleeding episodes in haemophilia patients with inhibitors to factor VIII (FVIII) and factor IX...
- Myocardial injury in patients with intracerebral hemorrhage treated with recombinant factor VIIaR M Sugg
Department of Neurology, The University of Houston Medical School, Houston, TX 77030, USA
Neurology 67:1053-5. 2006We report myocardial injury in 20 recombinant factor VIIa (rFVIIa) treated and 110 nontreated patients with intracerebral hemorrhage. Patients were treated or received standard medical management...
- On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life-threatening haemorrhage: focus on prothrombin activationGrigoris T Gerotziafas
Department of Haematology, Theagenion Cancer Hospital, 2 A Simeonidi Street, 54161 Thessaloniki, Greece
Br J Haematol 117:705-8. 2002..These data indicate that rFVIIa accelerated thrombin generation without significant increase of generated thrombin...
- Use of recombinant factor VIIa in patients with amniotic fluid embolism: a systematic review of case reportsBarbara L Leighton
Washington University in Saint Louis School of Medicine, St Louis, Missouri 63110, USA
Anesthesiology 115:1201-8. 2011..Recombinant factor VIIa (rVIIa) has been used to treat hemorrhage in AFE patients even though rVIIa can combine with circulating tissue ..
- Dual Direct Inhibitors of Thrombin and Factor XaUMESH RAMANLAL DESAI; Fiscal Year: 2012..4) In contrast, they inhibit factor IXa and factor VIIa with IC50 values 60-170-fold and >840-fold higher, respectively suggesting high selectivity for thrombin and ..
- Targeted Delivery of a Novel Synthetic Curcumin Analog, EF24 to Glioblastoma andMAMORU NONE SHOJI; Fiscal Year: 2012..have developed is EF24, a synthetic curcumin analog, which will be linked to enzymatically inactive coagulation factor VIIa (fVIIa), the high affinity ligand for TF that has exquisite specificity...
- Lipid Regulation of Thrombin GenerationBarry R Lentz; Fiscal Year: 2012..role in other key proteolytic reactions involved in blood coagulation? Factor IXa with its cofactor VIIIa and factor VIIa with its cofactor tissue factor activate factor X to Xa...
- TFPI ALPHA AND TFPI BETAGeorge J Broze; Fiscal Year: 2013..by applicant): Tissue factor pathway inhibitor (TFPI) produces factor Xa (FXa)-dependent feedback inhibition of factor VIIa/tissue factor (FVIIa/TF)-induced coagulation. In humans, TFPI is expressed as two isoforms...
- Factor VIIa Interaction with Endothelial Cell Protein C ReceptorVIJAYA MOHAN RAO LELLA; Fiscal Year: 2013..Recently, we have shown that factor VIIa (FVIIa) binds specifically to endothelial cell protein C receptor (EPCR) on endothelial cells...
- Expansion of intracranial hemorrhage by tPA after traumatic brain injuryABD ALROOF HIGAZI; Fiscal Year: 2013..tranexamic acid (TA) and may help explain the increased mortality that follows use of recombinant factor VIIa (rVIIa)...
- Association of tissue factor pathway inhibitor with endotheliumAlan E Mast; Fiscal Year: 2012..Inhibitor (TFPI) is an endothelial associated anticoagulant protein that directly inhibits the Tissue Factor-factor VIIa (TF-fVIIa) catalytic complex preventing intravascular thrombosis, disseminated intravascular coagulation, tumor ..
- MOLECULAR INTERACTIONS OF BLOOD COAGULATION FACTOR XAKatherine High; Fiscal Year: 1999Blood coagulation Factor X occupies a central role in the clotting cascade. It can be activated by either Factor VIIa-tissue factor (extrinsic tenase) or by Factor IXa-VIIIa-phospholipid (intrinsic tenase)...
- Structure and Function of Protein-Membrane Interactions in Blood ClottingChad M Rienstra; Fiscal Year: 2013..The primary focus of our studies is the membrane-bound complex of tissue factor and factor VIIa, the two-subunit enzyme responsible for triggering blood clotting in health and disease...
- AUTOIMMUNE MECHANISMS OF THROMBOSISRobert Roubey; Fiscal Year: 2004..autoantibodies and autoantibodies to tissue factor pathway inhibitor (TFPI), a critical inhibitor of both factor VIIa/TF and factor Xa...
- The Role of Tissue Factor-Factor VIIa-PAR2 Signaling in Breast Tumor ProgressionTROY MCEACHRON; Fiscal Year: 2010..Increased understanding of the metastatic disease process will enable the scientific and medical communities to make advances in therapeutics and treatment strategies. ..
- Functional Cooperation of Tissue Factor and IntegrinsWolfram Ruf; Fiscal Year: 2013..extrinsic coagulation pathway, is upregulated in cancer cells and the complex of TF with its ligand coagulation factor VIIa (FVIIa) contributes to cancer- associated thrombosis and activation of the host hemostatic system in metastasis...
- ROLE OF METAL IONS IN THE FUNCTION OF HUMAN FACTOR IXHoward Liebman; Fiscal Year: 1992..include studies of the activation of the mutant and partially carboxylated Factor lX proteins by Factor XIa and Factor VIIa-Tissue Factor, enzymatic activity of activated mutant and partially carboxylated Factor lX proteins and studies ..
- Induction of Tissue Factor by Patient Sera in HUSEric Grabowski; Fiscal Year: 2007..an antibody directed against activated factor X, recombinant-activated protein C, and active site-inhibited r-factor VIIa. A confirmation that shiga toxin and cytokines present in patient sera augment the TF pathway in our model ..
- Molecular Recognition in Factor VIIa Induced CoagulationS Bajaj; Fiscal Year: 2005This application is based upon the conviction that activation of factor X by the tissue factor/factor VIIa (TF/VIIa) complex represents a key step in the initiation of coagulation by the extrinsic pathway...
- MOLECULAR BIOLOGY AND PHYSIOLOGY OF HUMAN FACTOR VIISteven Idell; Fiscal Year: 1992..Factor VII is the first zymogen or, in its activated form, factor VIIa is the first serine protease which in association with tissue factor and calcium form the extrinsic pathway ..
- INHIBITORS OF THE EXTRINSIC BLOOD COAGULATION PATHWAYTERENCE BRUNCK; Fiscal Year: 1991..Synthetic peptides will mimic unique surface accessible regions of Factor VIIa, as determined by sequence and structure analysis...
- BLOOD COAGULATION HOMESTASIS: REGULATION OF TFPIAlan Schwartz; Fiscal Year: 2003..inhibitor of coagulation is tissue factor pathway inhibitor (TFPI), which produces feedback inhibition of the factor VIIa/tissue factor complex and directly binds and inhibits factor Xa...
- FACTOR X ACTIVATION BY THE EXTRINSIC PATHWAYSriram Krishnaswamy; Fiscal Year: 2006..The enzyme complex (extrinsic Xase) that catalyses this reaction is composed of the serine proteinase, factor VIIa, and the integral membrane protein, tissue factor, that associate tightly on a cellular or phospholipid surface ..
- Fluorogenic Assays for Factor Vlla and Tissue FactorRICHARD JENNY; Fiscal Year: 2006b>Factor VIIa and tissue factor (TF) are essential proteins for the initiation of blood coagulation. Blood coagulation is initiated when cryptic TF becomes exposed on the surface of vascular cells where it can bind circulating factor VIla...
- NEW THERAPIES FOR HEMOPHILIANigel Key; Fiscal Year: 2004..a multi- disciplinary approach to this problem, concentrating on bio-engineered clotting factors (mutants of factor VIIa with enhanced pro-coagulant activity, and human-porcine factor VIII hybrid molecules with reduced ..
- ENHANCED VITAMIN K DEPENDENT PROTEINSGary Nelsestuen; Fiscal Year: 2002..impact of membrane affinity (specific aim 1) on the enzyme activity of the activated forms of these proteins (factor VIIa and activated protein C, APC), including the impact of cofactor proteins, membrane content, and other ..
- TISSUE FACTOR IN BLOOD COAGULATIONYale Nemerson; Fiscal Year: 2002..We also are interested in the detailed structure of tissue factor in complex with the enzyme, factor VIIa and the next protein involved in the coagulation scheme, factor X...
- SELECTIVE CAPTURE AND QUANTITATION OF SERINE PROTEASESRICHARD JENNY; Fiscal Year: 1991..2) To expand and optimize CASSIA technology for the assay of additional serine proteases including thrombin Factor VIIa, Factor IXa, Factor Xa, and activated protein C; and 3) To evaluate the diagnostic potential of each assay ..
- SATURATION MUTAGENESIS OF ZEBRAFISH COAGULATION PATHWAYPudur Jagadeeswaran; Fiscal Year: 2003..blood coagulation through the extrinsic pathway is a threshold-mediated event influenced by relative levels of factor VIIa, tissue factor and TFPI activity...
- OPTIMIZATION OF AN EFFICACIOUS TUMOR VASCULAR THROMBOGENL Houston; Fiscal Year: 1999..ii) incorporate modifications to the structure human tissue factor (TF), which acts as a cofactor for factor VIIA, that have been shown to increase the safety and decrease the toxicity of TF and (iii) use structural elements ..
- THROMBOSIS: ETIOLOGY, RISK FACTORS AND TREATMENTRODGER MCEVER; Fiscal Year: 2005..and signaling functions of the endothelial protein C receptor, the membrane requirements of the tissue factor/factor VIIa complex, and the use of gene-targeted mice to study the functions of vascular adhesion and signaling molecules ..
- NOVEL INHIBITORS OF COAGULATION PROTEASESSUSAN TAMURA; Fiscal Year: 1991..g. Tissue Factor:Factor VIIa (TF:VIIa), Factor Xa, thrombin and kallikrein...
- INHIBITION OF TISSUE FACTOR MEDIATED ANGIOGENESISMamoru Shoji; Fiscal Year: 2001..This will be accomplished by coupling the agent to an inhibitor of coagulation factor VIIa, which possesses five times higher affinity for TF than VIIa...
- SERPIN-PROTEASE REACTION, HYDRATION AND GEOMETRY CHANGESMaria McGee; Fiscal Year: 2002..3. Characterization of hydration structure of tissue factor and tissue factor/factor VIIa complexes and its relationship to functional binding interaction...
- FONDAPARINUM IN CHILDREN WITH THROMBOSISGuy Young; Fiscal Year: 2007..Pharmacokinetic analyses as well as safety and efficacy determinations will be made which will provide valuable information on this new anticoagulant for pediatric patients. [unreadable] [unreadable]..
- Dose-finding, pharmacokinetic, safety and efficacy of bivalirudin in childrenGuy Young; Fiscal Year: 2009..More modern therapies are available but have not been systematically tested in children. This study will determine whether one such medication, bivalirudin is a safer and more effective alterative. ..
- INITIATION AND REGULATION OF BLOOD COAGULATIONVIJAYA MOHAN RAO LELLA; Fiscal Year: 2010..abstract_text> ..
- Nanoparticle targeting of cathepsin-L inhibitor and doxorubicin in breast cancerShaker Mousa; Fiscal Year: 2007..unreadable] [unreadable] [unreadable]..
- CELL MEDIATED HEMOSTASISHarold Roberts; Fiscal Year: 2004....
- PAR SIGNALING AND PROTECTIVE PATHWAYS IN INFLAMMATION AND SEPSISWolfram Ruf; Fiscal Year: 2010..3. ..
- TARGETING SIGNALING OF THE TISSUE FACTOR PATHWAYWolfram Ruf; Fiscal Year: 2007..abstract_text> ..
- Tissue Factor-factor Vlla signalingUsha Pendurthi; Fiscal Year: 2010..The proposed studies will provide valuable information in understanding how TF contributes to tumorigenesis. These studies will also provide clues on potential therapeutic targets for prevention of cancer progression. ..
- Pathophysiology of anti-B2GPI Antibodies in APSALISA WOLBERG; Fiscal Year: 2008..It is expected that these proposed studies will contribute to a fundamental understanding of pathogenic mechanisms for thrombosis in APS and lead to future investigations addressing therapeutic interventions in APS. ..
- Pathophysiology of thiamine-responsive anemia syndromeEllis Neufeld; Fiscal Year: 2006....
- 26th Princeton Conference on Cerebrovascular DiseaseJames Grotta; Fiscal Year: 2008..All presentations and discussion will be recorded and published. [unreadable] [unreadable] [unreadable]..
- Symphony Multiplex Peptide Synthesizer w/ VISION WorkstnKenneth Mann; Fiscal Year: 2004..There is currently no preparative HPLC system on the campus of the University of Vermont and this system is badly needed for many investigators. ..
- PE BIOSYSTEMS VOYAGER DE MALDI-TOFKenneth Mann; Fiscal Year: 2001..The fulfillment of the specific aims described in detail in the twelve research proposals would be facilitated by the addiction of a Voyager-DE MALDI-TOF ..
- FAT MEDIATED INSULIN SECRETION AND DIABETES IN ELDERLYGuenther Boden; Fiscal Year: 2003..We hope that this project will help to better understand the mechanisms by which obesity contributes to the development of NIDDM. ..
- BIACORE 3000PIERRE NEUENSCHWANDER; Fiscal Year: 2003....
- VASCULAR BIOLOGY IN CANCERThomas Edgington; Fiscal Year: 2006..Weekly seminars and review of data are conducted by each of the faculty members with their group. M.D., Ph.D. and M.D./Ph.D. candidates are recruited and prepared for an independent investigative career. ..
- HUMAN TISSUE FACTOR AND ITS PLASMA INHIBITORGeorge Broze; Fiscal Year: 2001..3) further characterize TFPIK1 gene-disrupted mice which have an isolated deficiency in TFPI-mediated factor VIIa/TF inhibition; 4) produce TFPI null mice and compare their phenotype with that of TFPIK1 mice; and 5) attempt ..
- Antithrombotic Gene TherapyPierre Zoldhelyi; Fiscal Year: 2006..We hypothesize that gene transfer of TFPI and PGHS-1 will achieve lasting vasoprotection without hemorrhagic risk. ..
- Designing Mechanism-based AnticoagulantsUmesh Desai; Fiscal Year: 2006..abstract_text> ..
- Outcome and Quality of Life after Diabetic StrokeBrett Kissela; Fiscal Year: 2007..It is the goal of the Prinicipal Investigator to become an expert in epidemiology and outcomes research and to use clinical research to improve the lives of diabetic patients with stroke. ..
- Free Fatty Acids and Hepatic Insulin ResistanceGuenther Boden; Fiscal Year: 2007..These studies will hopefully provide much needed information relative to important details and mechanisms of FFA induced hepatic insulin resistance. [unreadable] [unreadable]..
- Fat Induced Insulin Resistance and AtherosclerosisGuenther Boden; Fiscal Year: 2007..We believe that these studies will provide important new information relative to the mechanism by which obesity and FFAs cause IR and ASVD in human subjects. ..
- Vascular Biology of Tissue FactorWolfram Ruf; Fiscal Year: 2008..These studies have, and will continue to produce original data and advanced knowledge of the TF driven thrombotic and inflammatory diseases and new routes to reduce the impact of these diseases. ..
- Pathophysiologies Involving Hemostasis-related GenesFrancis Castellino; Fiscal Year: 2008..abstract_text> ..
- PRIMARY STRUCTURE OF PROTHROMBINKenneth Mann; Fiscal Year: 2008..The major aim of this project is to elucidate the structure/function relationships of this material with respect to factor V inactivation and to access its potential significance in the pathology of human thrombosis. ..
- Structural Mechanisms for the Inhibition of ThrombosisJAMES HUNTINGTON; Fiscal Year: 2009....
- Pathogenesis of HIV and HCV in Hemophilia: HGDSEdward Gomperts; Fiscal Year: 2004..This study will utilize state-of-the-art technology in a well-characterized cohort to expand the current understanding of host and immune factors that influence viral replication and clinical disease progression. ..
- EFFECTS OF TF/FVIIa INHIBITION IN CRP TRANSGENIC MICEChristopher Arnold; Fiscal Year: 2004..Together, these models will help determine the in vivo anti-inflammatory and antithrombotic properties of BCX-3607, a potential agent for the treatment of acute coronary syndromes. ..
- Functional Domains of Coagulation Factor VMichael Kalafatis; Fiscal Year: 2007..We have established a system to study phospholipids-driven macromolecular complex formation, which may be a model for the generation of complexes that form extra-and intra-cellularly. ..
- Structural Mechanisms of Factor IXa FunctionPIERRE NEUENSCHWANDER; Fiscal Year: 2009..As such, this work will foster the development of novel therapeutics for either coagulopathies or bleeding disorders. ..
- TFPI ALPHA AND TFPI BETAGeorge Broze; Fiscal Year: 2009..by applicant): Tissue factor pathway inhibitor (TFPI) produces factor Xa (FXa)-dependent feedback inhibition of factor VIIa/tissue factor (FVIIa/TF)-induced coagulation. In humans, TFPI is expressed as two isoforms...